Ibarra-Estrada MA, Briseño-Ramírez J, Chiquete E, Ruiz-Sandoval JL

Language: Spanish
References: 47
Page: 289-295
PDF size: 49.07 Kb.

ABSTRACT

In recent years it has been increasingly recognized the presence of acquired neuromuscular disease in the critically ill patient, either as a form of acute myopathy, polyneuropathy or persistent blockade by neuromuscular relaxing agents. Critical illness polyneuropathy (CIP) and myopathy (CIM) are characterized for the presence of weakness, manifested as a quadriparesia, usually flaccid and symmetrical with reduction and/or absence of deep tendon reflexes. Involvement of phrenic nerve, intercostal and accessory respiratory muscles, atrophy and contractile dysfunction of the diaphragm have been described as a cause of delayed mechanical ventilation weaning. Although routine electrophysiological examination sometimes cannot discriminate between patients with CIM and CIP, mainly because they usually coexist, it is useful to rule out other causes of neuromuscular weakness, being able to be practiced before sedation withdrawal. Despite some clinical trials propose as treatment options nutritional interventions with diverse supplements and antioxidants, intravenous immunoglobulin administration or activated protein C, none of them has demonstrated clinical utility. The only management so far is preventive, with emphasis on reducing or discontinuing glucocorticoids and neuromuscular blockers as soon as possible, reaching strict control on blood glucose with insulin, aggressive management of sepsis, early use of spontaneous breathing tests in patients with mechanical ventilation, anticipation of further medical complications and early rehabilitation.

REFERENCES

1. Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve 1998, 21: 610-7.

2. Fletcher SN, Kennedy DD, Ghosh IR. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003; 31: 1012-6.

3. Williams TA, Dobb GJ, Finn JC, Webb SA. Long-term survival from intensive care: a review. J Intensive Care Med 2005; 31: 1306-15.

4. MacFarlane I, Rosenthal F. Severe myopathy after status asthmaticus. Lancet 1977; 2: 615.

5. Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984; 47: 1223-31.

6. Bolton CF, Laverty DA, Brown JD, Witt NJ, Hahn AF, Sibbald WJ. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1986; 49: 563-73.

7. Hund E. Myopathy in critically ill patients. Crit Care Med 1999; 27: 2544-7.

8. Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327: 524-8.

9. Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med 2009; 37: S299-S308.

10. Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Pronovost PJ, Needham DM. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med 2007; 33: 1876-97.

11. De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand- Zaleski I, Boussarsar M, et al; Groupe de Réflexion et d€Etude des Neuromyopathies en Réanimation. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288: 2859-67.

12. Amaya-Villar R, Garnacho-Montero J, García-Garmendía JL, Madrazo- Osuna J, Garnacho-Montero MC, Luque R, Ortiz-Leyba C. Steroidinduced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2005; 31: 157-61.

13. Van Den Berghe, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-67.

14. de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, van der Meché FG. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001; 29: 2281-6.

15. Thiele RI, Jakob H, Hund E, Genzwuerker H, Herold U, Schweiger P, Hagl S. Critical illness polyneuropathy: a new iatrogenically induced syndrome after cardiac surgery? Eur J Cardiothorac Surg 1997; 12: 826-35.

16. Garnacho-Montero J, Madrazo-Osuna J, García-Garmendia JL, Ortiz- Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar A, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 2001; 27: 1288-96.

17. Druschky A, Herkert M, Radespiel-Tröger M, Druschky K, Hund E, Becker CM, Hilz MJ, et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001; 27: 686-93.

18. Thiele RI, Jakob H, Hund E, Tantzky S, Keller S, Kamler M, Herold U, Hagl S. Sepsis and catecholamine support are the major risk factors for critical illness polyneuropathy after open heart surgery. Thorac Cardiovasc Surg 2000; 48: 145-150.

19. Rudis MI, Guslits BJ, Peterson EL, Hathaway SJ, Angus E, Beis S, Zarowitz BJ. Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 1996; 24: 1749-56.

20. Powers SK, Kavazis AN, Levine S. Prolonged mechanical ventilation alters diaphragmatic structure and function. Crit Care Med 2009; 37: S347-S353.

21. Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry 2008; 79: 838-41.

22. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005; 32: 140-63.

23. Zink W, Kollmar R, Schwab S. Critical illness polyneuropathy and myopathy in the intensive care unit. Nat Rev Neurol 2009; 5(7): 372-9.

24. Di Giovanni S, Mirabella M, D€Amico A, Tonali P, Servidei S. Apoptotic features accompany acute quadriplegic myopathy. Neurology 2000; 55: 854-858.

25. Latronico N, Guarneri B. Critical illness myopathy and neuropathy. Minerva Anestesiol 2008; 74: 319-23.

26. Zochodne DW, Bolton CF, Thompson RT, Driedger AA, Hahn AF, Gilbert JJ. Myopathy in critical illness. Muscle Nerve 1986, 9: 652.

27. Bolton CF, Young GB, Zochodne DW. The neurological complications of sepsis. Ann Neurol 1993; 33: 94-100.

28. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy. Curr Opin Crit Care 2010; 16: 123-7.

29. Latronico N, Fenzi F, Recupero D, Guarneri B, Tomelleri G, Tonin P, et al. Critical illness myopathy and neuropathy. Lancet 1996; 347: 1579-82.

30. Khan J, Harrison TB, Rich MM, Moss M. Early development of critical illness myopathy and neuropathy in patients with severe sepsis. Neurology 2006; 67: 1421-5.

31. Latronico N, Bertolini G, Guarneri B, Botteri M, Peli E, Andreoletti S, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care 2007; 11: R11.

32. Coakley JH, Nagendran K, Yarwood GD, Honavar M, Hinds CJ. Patterns of neurophysiological abnormality in prolonged critical illness. Intensive Care Med 1998; 24: 801-7.

33. Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol 1996; 40: 645-54.

34. Stibler H, Edstrom L, Ahlbeck K, Remahl S, Ansved T. Electrophoretic determination of the myosin/actin ratio in the diagnosis of critical illness myopathy. Intensive Care Med 2003; 29: 1515-27.

35. Latronico N, Shehu I, Seghelini E. Neuromuscular sequel of critical illness. Curr Opin Crit Care 2005; 11: 381-90.

36. Ropper AH. The Guillain-Barre´ syndrome. N Engl J Med 1992; 326: 1130-6.

37. Wittbrodt ET. Drugs and myasthenia gravis: an update. Arch Intern Med 1997; 157: 399-408.

38. Wijdicks EF. Neurologic complications of critical illness. Oxford: Oxford University Press; 2002.

39. Maramattom BV, Wijdicks EF. Acute neuromuscular weakness in the intensive care unit. Crit Care Med 2006; 34: 2835-2841.

40. Latronico N. Neuromuscular alterations in the critically ill patients: critical illness myopathy, critical illness neuropathy, or both? Intensive Care Med 2003; 29: 1411-3.

41. Berard MP, Zazzo JF, Condat P, Vasson MP, Cynober L. Total parenteral nutrition enriched with arginine and glutamate generates glutamine and limits protein catabolism in surgical patients hospitalized in intensive care units. Crit Care Med 2000; 28: 3637-44.

42. Heyland DK, Dhaliwal R, Day AG, Muscedere J, Drover J, Suchner U, Cook D; Canadian Critical Care Trials Group. Reducing deaths due to oxidative stress (The REDOXS Study): Rationale and study design for a randomized trial of glutamine and an antioxidant supplementation in critically-ill patients. Proc Nutr Soc 2006; 65: 250-63.

43. Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997; 23: 1144-9.

44. Lowry SF. Sepsis and its complications: clinical definitions and therapeutic prospects. Crit Care Med 1994; 22: S1-S2.

45. Brochard L, Thille AW. What is the proper approach to liberating the weak from mechanical ventilation? Crit Care Med 2009; 37: S410- S415.

46. Lacomis D. Management of generalized weakness in medical and surgical intensive care units. In: Noseworthy J (Ed.) Neurological Therapeutics, Principles and Practice, 2nd Ed. London: Martin Dunitz Ltd; 2003.

47. Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 2009: CD006832.